Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies-Reference-Cited by-同舟云学术

Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies

Published:2016-07-04 Issue:4 Volume:43 Page:427-446
ISSN:1567-567X
Container-title:Journal of Pharmacokinetics and Pharmacodynamics
language:en
Short-container-title:J Pharmacokinet Pharmacodyn

Author:

Glassman Patrick M.,Balthasar Joseph P.^ORCID

Funder

Center for Protein Therapeutics

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s10928-016-9482-0.pdf

Reference84 articles.

1. Reichert JM (2015) Antibodies to watch in 2016. mAbs:1-8. doi: 10.1080/19420862.2015.1125583

2. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84(5):548–558. doi: 10.1038/clpt.2008.170

3. Hooks MA, Wade CS, Millikan WJ Jr (1991) Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11(1):26–37

4. Sohn W, Simiens MA, Jaeger K, Hutton S, Jang G (2014) The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review. Br J Clin Pharmacol 78(3):477–487. doi: 10.1111/bcp.12355

5. Bugelski PJ, Martin PL (2012) Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol 166(3):823–846. doi: 10.1111/j.1476-5381.2011.01811.x

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling on in vivo disposition and cellular transportation of RNA lipid nanoparticles via quantum mechanics/physiologically-based pharmacokinetic approaches;Acta Pharmaceutica Sinica B;2024-07

2. Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins;Journal of Pharmacokinetics and Pharmacodynamics;2024-05-01

3. Lymphatic distribution considerations for subunit vaccine design and development;Vaccine;2024-04

4. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics;Journal of Pharmacokinetics and Pharmacodynamics;2024-02-24

5. Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET;EJNMMI Research;2024-02-15